Mast cell tumor pathophysiology

Jump to: navigation, search

Mast cell tumor Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Mast Cell Tumor from other Diseases

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

Diagnostic criteria

Staging

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography or Ultrasound

CT Scan

MRI

Biopsy

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Mast cell tumor pathophysiology On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Mast cell tumor pathophysiology

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Mast cell tumor pathophysiology

CDC on Mast cell tumor pathophysiology

Mast cell tumor pathophysiology in the news

Blogs on Mast cell tumor pathophysiology

Directions to Hospitals Treating Mast cell tumor

Risk calculators and risk factors for Mast cell tumor pathophysiology

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1];Associate Editor(s)-in-Chief: Suveenkrishna Pothuru, M.B,B.S. [2]

Overview

Mast cell tumor arises from the mast cell, which is a type of white blood cell involved in the inflammatory process. The progression to mast cell tumor usually involves the uncontrolled stimulation of the receptor for stem cell factor following mutation of C-kit cell surface receptor. On microscopic histopathological analysis, mast cells in the superficial and mid dermis that are lymphocyte like with dense granular cytoplasm which tend to be more abundant around blood vessels is characteristic finding of mast cell tumor.

Pathophysiology

Mast Cell

Genetics

Microscopic Pathology

  • Tend to be more abundant around vessels
  • Eosinophils may present

References

  1. Moon TC, Befus AD, Kulka M (2014). "Mast cell mediators: their differential release and the secretory pathways involved". Front Immunol. 5: 569. doi:10.3389/fimmu.2014.00569. PMID 25452755.
  2. Krystel-Whittemore M, Dileepan KN, Wood JG (2015). "Mast Cell: A Multi-Functional Master Cell". Front Immunol. 6: 620. doi:10.3389/fimmu.2015.00620. PMID 26779180.
  3. Metcalfe DD (2005). "Regulation of normal and neoplastic human mast cell development in mastocytosis". Trans. Am. Clin. Climatol. Assoc. 116: 185–203, discussion 203–4.
  4. Ramsay DB, Stephen S, Borum M, Voltaggio L, Doman DB (December 2010). "Mast cells in gastrointestinal disease". Gastroenterol Hepatol (N Y). 6 (12): 772–7. PMC 3033552. PMID 21301631.
  5. Ahmed M, Kesavan M, Jilani BN, Ahmed S, Deeb L (June 2016). "Systemic Mastocytosis as an Unconventional Cause of Variceal Bleeding: Think Outside the Box". Cureus. 8 (6): e629. doi:10.7759/cureus.629. PMC 4935436. PMID 27433408.
  6. Molderings, Gerhard J; Brettner, Stefan; Homann, Jürgen; Afrin, Lawrence B (2011). "Mast cell activation disease: a concise practical guide for diagnostic workup and therapeutic options". Journal of Hematology & Oncology. 4 (1): 10. doi:10.1186/1756-8722-4-10. ISSN 1756-8722.
  7. Longley BJ, Morganroth GS, Tyrrell L, Ding TG, Anderson DM, Williams DE, Halaban R (May 1993). "Altered metabolism of mast-cell growth factor (c-kit ligand) in cutaneous mastocytosis". N. Engl. J. Med. 328 (18): 1302–7. doi:10.1056/NEJM199305063281803. PMID 7682288.
  8. Galli SJ, Tsai M, Wershil BK (April 1993). "The c-kit receptor, stem cell factor, and mast cells. What each is teaching us about the others". Am. J. Pathol. 142 (4): 965–74. PMC 1886888. PMID 7682764.
  9. Chatterjee A, Ghosh J, Kapur R (July 2015). "Mastocytosis: a mutated KIT receptor induced myeloproliferative disorder". Oncotarget. 6 (21): 18250–64. doi:10.18632/oncotarget.4213. PMID 26158763.
  10. Kristensen T, Vestergaard H, Møller MB (March 2011). "Improved detection of the KIT D816V mutation in patients with systemic mastocytosis using a quantitative and highly sensitive real-time qPCR assay". J Mol Diagn. 13 (2): 180–8. doi:10.1016/j.jmoldx.2010.10.004. PMC 3279709. PMID 21354053.
  11. Schwaab J, Schnittger S, Sotlar K, Walz C, Fabarius A, Pfirrmann M, Kohlmann A, Grossmann V, Meggendorfer M, Horny HP, Valent P, Jawhar M, Teichmann M, Metzgeroth G, Erben P, Ernst T, Hochhaus A, Haferlach T, Hofmann WK, Cross NC, Reiter A (October 2013). "Comprehensive mutational profiling in advanced systemic mastocytosis". Blood. 122 (14): 2460–6. doi:10.1182/blood-2013-04-496448. PMID 23958953.
  12. Traina F, Visconte V, Jankowska AM, Makishima H, O'Keefe CL, Elson P, Han Y, Hsieh FH, Sekeres MA, Mali RS, Kalaycio M, Lichtin AE, Advani AS, Duong HK, Copelan E, Kapur R, Olalla Saad ST, Maciejewski JP, Tiu RV (2012). "Single nucleotide polymorphism array lesions, TET2, DNMT3A, ASXL1 and CBL mutations are present in systemic mastocytosis". PLoS ONE. 7 (8): e43090. doi:10.1371/journal.pone.0043090. PMC 3419680. PMID 22905207.
  13. Chan EC, Bai Y, Bandara G, Simakova O, Brittain E, Scott L, Dyer KD, Klion AD, Maric I, Gilfillan AM, Metcalfe DD, Wilson TM (October 2013). "KIT GNNK splice variants: expression in systemic mastocytosis and influence on the activating potential of the D816V mutation in mast cells". Exp. Hematol. 41 (10): 870–881.e2. doi:10.1016/j.exphem.2013.05.005. PMID 23743299.
  14. Berezowska S, Flaig MJ, Ruëff F, Walz C, Haferlach T, Krokowski M, Kerler R, Petat-Dutter K, Horny HP, Sotlar K (January 2014). "Adult-onset mastocytosis in the skin is highly suggestive of systemic mastocytosis". Mod. Pathol. 27 (1): 19–29. doi:10.1038/modpathol.2013.117. PMID 23807778.
  15. Tefferi A, Lim KH, Abdel-Wahab O, Lasho TL, Patel J, Patnaik MM, Hanson CA, Pardanani A, Gilliland DG, Levine RL (July 2009). "Detection of mutant TET2 in myeloid malignancies other than myeloproliferative neoplasms: CMML, MDS, MDS/MPN and AML". Leukemia. 23 (7): 1343–5. doi:10.1038/leu.2009.59. PMC 4654626. PMID 19295549.

Linked-in.jpg